证券日报网讯汉森制药（002412）9月26日在互动平台回答投资者提问时表示，公司在产品研发方面， 中药新药苁蓉颗粒正处于工艺中试放大研究阶段。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司今年的研发计划里面，创新药占比多少？ 汉森制药（002412.SZ）9月26日在投资者互动平台表示，公司在产品研发方面，中药新药苁蓉颗粒正处 于工艺中试放大研究阶段。具体情况请参考公司2024年度报告。 ...

Group 1 - The company is currently in the process of scaling up the production of its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot testing phase [1] - The Tianma Xingnao Capsule is designed to nourish the liver and kidneys, alleviate pain, and is used for symptoms related to liver and kidney deficiency, such as headaches, dizziness, memory decline, insomnia, sluggishness, tinnitus, and lower back pain [1] - For detailed information, the company refers investors to its 2024 annual report [1]